Tacrolimus-induced nephrotoxicity and genetic variability: A review

Annals of Transplantation

Volumn 17, Issue 2, 2012, Pages 111-121

  Gijsen, Violette M G J ^a,b   Madadi, Parvaz ^a   Dubé, Marie Pierre ^c,d   Hesselink, Dennis A ^e   Koren, Gideon ^a   de Wildt, Saskia N ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c MONTREAL HEART INSTITUTE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABCB1; ACE; CYP3A5; Genetics; Nephrotoxicity; Tacrolimus; TGF

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

CARDIAC GRAFT REJECTION; DRUG INDUCED DISEASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NEPHROTOXICITY; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW;

EID: 84863539411     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.883229     Document Type: Review

References (47)

1. Chandrakantan A, de Mattos AM, Naftel D et al: Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience. Clin J Am Soc Nephrol, 2006; 1(4): 832-36
2. Venkataramanan R, Swaminathan A, Prasad T et al: Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet, 1995; 29(6): 404-30
3. Astellas Pharma Canada Inc. Product Monograph Prograf (tacrolimus). 2005
4. Staatz CE, Goodman LK, Tett SE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet, 2010; 49(3): 141-75
5. Malinowski M, Pratschke J, Lock J et al: Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. Ann Transplant, 2010; 15(3): 60-65
6. Lewandowska L, Matuszkiewicz-Rowinska J: Acute kidney injury after procedures of orthotopic liver transplantation. Ann. Transplant, 2011; 16(2): 103-8
7. Wallemacq PE, Furlan V, Moller A et al: Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet, 1998; 23(3): 367-70
8. Ojo AO, Held PJ, Port FK et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 2003; 349(10): 931-40
9. Kaufman DB, Shapiro R, Lucey MR et al: Immunosuppression: practice and trends. Am J Transplant, 2004; 4(Suppl.9): 38-53
10. Naesens M, Kuypers DRJ, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol, 2009; 4(2): 481-508
11. Neu AM, Ho PLM, Fine RN et al: Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant, 2003; 7(3): 217-22
12. Jain S, Bicknell GR, Nicholson ML: Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg, 2000; 87(11): 1563-68
13. Filler G, Trompeter R, Webb NJA et al: Oneyear glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs. cyclosporine microemulsion. Transplant Proc, 2002; 34(5): 1935-38
14. McDiarmid SV, Colonna JO, Shaked A et al: Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation, 1993; 55(6): 1328-32
15. Ellis D: Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol, 1995; 9(4): 487-94
16. Dai D, Zeldin DC, Blaisdell JA et al: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 2001; 11(7): 597-607
17. Dai Y, Hebert MF, Isoherranen N et al: Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos, 2006; 34(5): 836-47
18. Kuehl P, Zhang J, Lin Y et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001; 27(4): 383-91
19. Muraki Y, Usui M, Isaji S et al: Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann Transplant, 2011; 16(4): 55-62
20. Wu P, Ni X, Wang M et al: Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Ann Transplant, 2011; 16(1): 54-60
21. Saito K, Miyake S, Moriya H et al: Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem, 2003; 36(7): 511-18
22. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther, 2004; 75(1): 13-33
23. Saeki T, Ueda K, Tanigawara Y et al: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem, 1993; 268(9): 6077-80
24. Randhawa PS, Shapiro R, Jordan ML et al: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol, 1993; 17(1): 60-68
25. Randhawa PS, Saad RS, Jordan M et al: Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. Transplantation, 1999; 67(1): 85-89
26. Navar LG, Inscho EW, Majid SA et al: Paracrine regulation of the renal microcirculation. Physiol Rev, 1996; 76(2): 425-536
27. Imig JD: Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol, 2000; 279(6): F965-981
28. Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health, 1998; 52(6): 377-84
29. Deeks JJ, Dinnes J, D'Amico R et al: Evaluating non-randomised intervention studies. Health Technol Assess, 2003; 7(27): iii-x, 1-173
30. Fukudo M, Yano I, Yoshimura A et al: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics, 2008; 18(5): 413-23
31. Kuypers DRJ, de Jonge H, Naesens M et al: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther, 2007; 82(6): 711-25
32. Chen JS, Li LS, Cheng DR et al: Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc, 2009; 41(5): 1557-61
33. Quteineh L, Verstuyft C, Furlan V et al: Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol, 2008; 103(6): 546-52
34. Klauke B, Wirth A, Zittermann A et al: No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant, 2008; 27(7): 741-45
35. Naesens M, Lerut E, de Jonge H et al: Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol, 2009; 20(11): 2468-80
36. Kuypers DRJ, Naesens M, de Jonge H et al: Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit, 2010; 32(4): 394-404
37. Hebert MF, Dowling AL, Gierwatowski C et al: Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics, 2003; 13(11): 661-74
38. van de Wetering J, Weimar CHE, Balk AHMM et al: The impact of transforming growth factorbeta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation, 2006; 82(12): 1744-48
39. Smith HE, Jones JP, Kalhorn TF et al: Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics, 2008; 18(11): 943-53
40. Gallon L, Akalin E, Lynch P et al: ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation, 2006; 81(3): 463-68
41. Grenda R, Prokurat S, Ciechanowicz A et al: Evaluation of the genetic background of standard- immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients--a retrospective tudy. Ann. Transplant, 2009; 14(3): 18-24
42. Hawwa AF, McKiernan PJ, Shields M et al: Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol, 2009; 68(3): 413-21
43. Lamba J, Strom S, Venkataramanan R et al: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther, 2006; 79(4): 325-38
44. Hosohata K, Masuda S, Yonezawa A et al: MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res, 2009; 26(7): 1590-95
45. Sellares J, de Freitas DG, Mengel M et al: Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence. Am J Transplant, 2012; 12(2): 388-99
46. Snanoudj R, Royal V, Elie C et al: Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant, 2011; 11(12): 2635-46
47. Grimshaw J, Scheet P, Gwinn M et al: Strengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest, 2009; 39(4): 247-66